HORMONE SENSITIVE PROSTATE CANCER

This early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in men with prostate cancer that has spread and is no longer responding to standard treatments. The drug delivers a radioactive payload directly to cancer cells that have a specific marker (PSMA). The study…

This study tested whether adding enzalutamide to standard hormone therapy (leuprolide) can delay the spread of prostate cancer in men with high-risk disease that has not yet spread. Over 1,000 men whose cancer progressed after initial treatment (surgery or radiation) participated…

This study tests whether adding the drug capivasertib to standard hormone therapy (abiraterone plus ADT) can slow cancer growth better than standard therapy alone in men with a specific type of advanced prostate cancer that has spread and lacks a protein called PTEN. About 1,000 …

This study looks at whether testosterone levels return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will take the drugs for two years, then stop to see if their testosterone recovers. T…

This study tests a combination of hormone therapy, chemotherapy (docetaxel), and an immunotherapy drug (nivolumab) in 60 men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively.…

This study tracks how well treatment is working in men with metastatic hormone-sensitive prostate cancer using special PET scans (PSMA-PET). Twenty participants will get a scan before starting standard therapy and another after 6 months. The goal is to see if these scans can help…

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…